However, very limited data is available from clinical trials—a phase 1 clinical study in healthy individuals (lean to overweight) with a new unimolecular GLP-1, GIP, and glucagon receptor triagonist (SAR441255) showed that the triagonist improved glycaemic control during a mixed-meal tolerance test and was well tolerated.134 Additionally, a recent abstract presented the results of a 12-week, phase 1 study, where the safety and tolerability of multiple doses of another GLP-1/GIP/glucagon co-agonist (LY3437943) compared with placebo were assessed in 72 people with T2D. Here, GIP is linked to type 2 diabetes mellitus.